688085 Shanghai Sanyou Medical Co., Ltd
- 18.04
- +0.19+1.06%
Shanghai Sanyou Medical Co., Ltd News
Shanghai Yuzheng, shareholder of Sanyou Medical (688085.SH), plans to reduce its holdings by no more than 1.6%
According to the Zhitong Finance App, Sanyou Medical (688085.SH) issued an announcement. Shanghai Yizheng, the shareholder holding 5.07% of its shares, plans to reduce its holdings of the company's shares by no more than 3.9752 million shares through bulk transactions due to its own capital needs. The proposed reduction of shares accounts for 1.6% of the company's total share capital.
Shanghai Sanyou Medical's French Unit Gets Nod to Market Jazz Spinal System in US; Shares Up 3%
Shanghai Sanyou Medical's (SHA:688085) French subsidiary, Implanet, received the 510(k) certification from the US Food and Drug Administration to market its Jazz spinal internal fixation system in the
Sanyou Medical (688085.SH): The holding company Implanet spinal fixation system obtained US FDA 510 (K) certification
On May 8, GLONGHUI | Sanyou Healthcare (688085.SH) announced that the French holding company Implanet recently received a notice from U.S.FoodDrugAdministration (US Food and Drug Administration, “FDA”), and the holding company Implanet's spinal fixation system has obtained US FDA 510 (K) certification. The JazzSpinalSystem, an internal spinal fixation system approved by Implanet in France, uses the company's full set of ZEUS spinal system files. The system is a
Shanghai Sanyou Medical Gets Registration Certificate for Peek Medical Product
China's National Medical Products Administration granted Shanghai Sanyou Medical (SHA:688085) a medical device registration certificate for its Peek polyetheretherketone anchor with wire, according to
Sanyou Medical (688085.SH) plans to wholly own Mizuki Tianpeng, a subsidiary in the field of ultrasound surgical equipment
Zhitong Finance App News, Sanyou Medical (688085.SH) announced that the company plans to acquire 37.1077% of the shares in Beijing Shuimu Tianpeng Medical Technology Co., Ltd. (“Mizuki Tianpeng”) held by Cao Qun and Xunong in total, and the Shanghai Yanzhan Enterprise Management Partnership (Limited Partnership) (“Shanghai Huanzhan”) (“Shanghai Huanzhan”) 98.9986% of the limited partner's investment share through the subsidiary Tuoteng (Suzhou) Medical Technology Co., Ltd. through cash acquisition of Zhanggang Tianpeng (“Mizuki Tianpeng”) hold Shanghai is still looking at 1.001
Sanyou Healthcare (688085.SH): Net loss of 2,095,800 yuan in the first quarter
Gelonghui, April 25 | Sanyou Medical (688085.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 86.4293 million yuan, a year-on-year decrease of 46.26%; net profit attributable to shareholders of listed companies - 2,0955,800 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 2,9516 million; and basic earnings per share - 0.01 yuan.
Calculating The Intrinsic Value Of Shanghai Sanyou Medical Co., Ltd (SHSE:688085)
Key Insights The projected fair value for Shanghai Sanyou Medical is CN¥16.87 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥17.97 suggests Shanghai Sanyou Medical is potentiall
Retail Investors Invested in Shanghai Sanyou Medical Co., Ltd (SHSE:688085) Copped the Brunt of Last Week's CN¥373m Market Cap Decline
Key Insights The considerable ownership by retail investors in Shanghai Sanyou Medical indicates that they collectively have a greater say in management and business strategy 51% of the business is
Sanyou Medical (688085.SH): The actual controller increased its total holdings by 25.20.28 million yuan and completed the increase in shares
Gelonghui March 20 | Sanyou Medical (688085.SH) announced that as of March 20, 2024, the company's actual controllers, Mr. Xu Nong, Mr. Michael MingyanLiu (Liu Mingyan), and Mr. DavidFan (Fan Xianglong), increased their holdings by a total of 25.202,800 yuan, increasing their holdings by 1,597,464 shares, accounting for 0.64%. Among them, Mr. Xu Nong increased his holdings of the company's shares by 1,043,387 shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.42% of the company's total share capital, with an increase of 1,600
Sanyou Medical (688085.SH): The overall number of terminal surgeries has further increased, and the number of products shipped has increased markedly
Gelonghui, March 19 | Sanyou Medical (688085.SH) said on the interactive platform that in 2023, due to the implementation of the national procurement of high-value spinal consumables, the company's spinal product terminal admission price dropped sharply, leading to a decline in the company's operating income and net profit. However, the company's sales team actively implemented the company's sales plan and used collection to enter the company's sales gap area to increase terminal hospital coverage. The company's overall terminal operation volume further increased, and the number of products shipped increased markedly. In the future, the company will continue to strengthen therapeutic innovation and sales expansion, continue to deepen the decline in sales channels, and actively expand the international market
There Are Reasons To Feel Uneasy About Shanghai Sanyou Medical's (SHSE:688085) Returns On Capital
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One common approach is to try and find a company with returns on capital employed (RO
Sanyou Medical (688085.SH): Actual controller increases shareholding
Ge Longhui, Feb. 26 | Sanyou Medical (688085.SH) announced that as of February 26, 2024, Mr. Xu Nong had increased his holdings of the company's shares by 623,240 shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for 0.25% of the company's total share capital, with an increase of 9.1083 million yuan; Mr. Michael MingyanLiu (Liu Mingyan) increased his holdings of the company's shares through centralized bidding through the Shanghai Stock Exchange trading system, accounting for a total share capital increase of 260,778 shares, accounting for 0.11% of the company's total share capital. 4,3297 million yuan, total increase in holdings
Sanyou Healthcare (688085.SH): Net profit in 2023 fell 52.2% year on year
Gelonghui, Feb. 23, 丨 Sanyou Medical (688085.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total revenue of 466.673 million yuan, a year-on-year decrease of 29.04%; R&D expenses of 6380.1 million yuan, an increase of 5.67%; R&D investment accounted for 13.85%, an increase of 4.55 percentage points over the same period last year; realized net profit attributable to the owner of the parent company after deducting non-recurring profit and loss, a year-on-year decrease of 52.20%; achieved net profit attributable to the owner of the parent company after deducting non-recurring profit and loss 6,091.31 million yuan,
Sanyou Medical (688085.SH): One of the actual controllers plans to increase the company's shares by 4 million yuan to 6 million yuan
Gelonghui, Feb. 23: Sanyou Medical (688085.SH) announced that based on confidence in the future development of the company and recognition of long-term investment value, Mr. DavidFan (Fan Xianglong), one of the actual controllers, plans to use his own capital or self-raised capital to increase the company's shares through the Shanghai Stock Exchange system from February 26, 2024 to April 30, 2024. The amount of this increase in holdings is not less than RMB 400,000 and no more than RMB 60 million.
Sanyou Medical (688085.SH): The two actual controllers plan to increase their total shares by 20 million yuan to 40 million yuan
Gelonghui, Feb. 7 | Sanyou Medical (688085.SH) announced that one of the company's actual controllers, Mr. Michael Mingyan Liu (Liu Mingyan), and one of the actual controllers, director and general manager, Mr. Xu Nong, intend to use their own capital or self-financing to increase their shares through the Shanghai Stock Exchange system from February 8, 2024 to April 30, 2024 through centralized bidding. 20 million yuan and no more than
Sanyou Medical (688085.SH): Shareholder Shanghai Yuzheng made a bulk transaction and reduced its shares by 1.35%
Gelonghui, January 29丨Sanyou Medical (688085.SH) announced that on January 29, 2024, the company received a “Notice Letter Concerning a Change in Share Equity Exceeding 1%” from Shanghai Yuzheng, the company's shareholder. From January 25, 2024 to January 29, 2024, Shanghai Yizheng reduced its holdings of the company's shares by 3.344,600 shares through bulk transactions, accounting for 1.35%.
Should Weakness in Shanghai Sanyou Medical Co., Ltd's (SHSE:688085) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Shanghai Sanyou Medical (SHSE:688085) has had a rough three months with its share price down 23%. However, the company's fundamentals look pretty decent, and long-term financials are usually aligned
Sanyou Medical (688085.SH): Net profit is expected to drop 50.21% to 60.7% year on year in 2023
Gelonghui, January 23丨Sanyou Medical (688085.SH) announced that according to preliminary estimates by the company's finance department, net profit attributable to the owner of the parent company is expected to be 75.0 million yuan to 95.0 million yuan in 2023. Compared with the same period last year, it is expected to decrease 95.818 million yuan to 11.5818 million yuan, a year-on-year decrease of 50.21% to 60.70%. The company expects net profit from non-recurring profit and loss attributable to owners of the parent company to be between RMB 53.0 million and RMB 65.0 million in 2023, compared with the same period last year
Is There An Opportunity With Shanghai Sanyou Medical Co., Ltd's (SHSE:688085) 32% Undervaluation?
Key Insights Shanghai Sanyou Medical's estimated fair value is CN¥26.68 based on 2 Stage Free Cash Flow to Equity Shanghai Sanyou Medical is estimated to be 32% undervalued based on current share pr
Shanghai Sanyou Medical Gets US FDA's Nod to Market Intervertebral Fusion Products
Shanghai Sanyou Medical (SHA:688085) obtained clearance to market its metal additive manufacturing intervertebral fusion series products in the US. The US Food and Drug Administration's 510(K) certifi
Analysis
Price Target
No Data
